Stock EVT EVT LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages EVT Limited

Equities

EVT

AU000000EVT1

Market Closed - Australian S.E.
Other stock markets
 07:10:44 26/04/2024 BST 		5-day change 1st Jan Change
11.75 AUD -3.37% Intraday chart for EVT Limited -1.01% -3.92%
04-24 Germany's Evotec Appoints Permanent CEO MT
04-18 Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Germany's Evotec Appoints Permanent CEO
EVT's Net Profit Declines 72% in Fiscal H1 on Thredbo Impact
EVT Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Evotec's US Unit Expands Collaboration vs HIV with Advanced BioScience Laboratories
Evotec Reiterates Trading Regulations Compliance Amid Former CEO’s Late Stock Trades Disclosure
Evotec Receives $25 Million Under Neuroscience Collaboration with Bristol Myers Squibb
Correction: Evotec, Owkin Team Up on AI-powered Research Across Oncology, Immunology, Inflammation
Evotec, Owken Team Up on AI-powered Research Across Oncology, Immunology, Inflammation
Evotec CEO to Step Down in 2026; Interim Successor Appointed
Evotec Secures Grant for Teratogenicity Platform
Evotec Partners With German Institution for Expanded Autoimmune Diseases Patients Database; Shares Up
Evotec, Glycotope Partner on Immune Cell Bispecifics Development Against Tumor
Evotec Signs Strategic Oncology-focused Partnership With Dewpoint Therapeutics
EVT Limited Provides Earnings Guidance for the Full Year 2023
Evotec Grants Three Partners Access to R&D Platform in Support of Biotech Innovation
Evotec, Novo Nordisk Partner for Translational Drug Discovery Accelerator
EVT Limited Announces Ordinary Fully Franked Dividend for the Twelve Months Ended June 30, 2023, Payable on September 28, 2023
EVT Limited Reports Earnings Results for the Full Year Ended June 30, 2023
EVT Limited acquired Freehold interest in 54 Cook Street, Auckland for NZD 32.2 million.
Evotec Sign Exclusive Global License Deal with Bristol Myers Squibb
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News EVT Limited
  5. Other languages